SEOUL, December 12 (AJP) - Kakao Healthcare said Friday it has signed an exclusive supply agreement with Dexcom, giving the South Korean digital health platform sole distribution rights for Dexcom's continuous glucose monitoring (CGM) products in South Korea.
Dexcom is a U.S.-based medical technology company specializing in CGM systems for people with diabetes.
Under the deal, the two companies will expand real-time blood glucose management services using Dexcom’s CGM lineup, including the Dexcom G7. Kakao Healthcare will oversee domestic distribution and market operations to broaden access to CGM devices and grow the user base amid rising demand for digital health services.
Kakao Healthcare said it aims to integrate its platform technology with Dexcom’s biosensing capabilities to advance data-driven chronic disease management and develop more precise, personalized health models.
The agreement follows roughly 18 months of collaboration. Dexcom reviewed Kakao Healthcare’s technology, digital infrastructure and distribution potential before formalizing the partnership. The companies also plan to widen their focus beyond glucose monitoring by incorporating lifestyle data — such as exercise, diet, sleep and stress — to enhance personalized care services.
Kakao Healthcare said the partnership will help strengthen its AI- and mobile-based healthcare platform, improve digital tools and engagement systems, and expand its omnichannel care offerings to solidify its position in the domestic digital health market.
“Through our partnership with Kakao Healthcare, access to Dexcom G7 in South Korea will improve and our vision for global digital connectivity will advance,” Jennifer Cho, Dexcom’s head of APAC, said in a press release. She said the collaboration reflects Dexcom’s commitment to incorporating AI-driven digital features into future products.
Kakao Healthcare CEO Hwang Hee said the extended collaboration has deepened the relationship between the two companies and is expected to support expansion into hospital services through synergies with Cha CareS and Cha AI Healthcare under South Korea’s Cha Bio Group.
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.